Drug Class Detail

Drug Class VEGFR2 Antibody


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
TRPH 011 VEGFR2 Antibody 4 Limited information is currently available on TRPH 011, a putative human bispecific antibody targeting vascular endothelial growth factor receptor 2 (KDR) and tyrosine kinase receptor 2 (Tie2) (Aug, 2018).
Ramucirumab Cyramza LY3009806 VEGFR2 Antibody 4 Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (NCI Drug Dictionary). Cyramza (ramucirumab) is approved for gastric and gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and colorectal cancer (FDA.gov).
unspecified VEGFR2 antibody Experimental anti-VEGFR2 VEGFR2 Antibody 4
Tanibirumab TTAC-0001 VEGFR2 Antibody 4 Tanibirumab (TTAC-0001) is a monoclonal antibody directed against KDR (VEGFR2), which may inhibit tumor angiogenesis (PMID: 21910042).
Molecular Profile Protein Effect Treatment Approaches